This document is an excerpt from the EUR-Lex website
Document 52024M11609
Prior notification of a concentration (Case M.11609 – KKR / IMPILO / IMMEDICA) – Candidate case for simplified procedure
Prior notification of a concentration (Case M.11609 – KKR / IMPILO / IMMEDICA) – Candidate case for simplified procedure
Prior notification of a concentration (Case M.11609 – KKR / IMPILO / IMMEDICA) – Candidate case for simplified procedure
PUB/2024/771
OJ C, C/2024/4990, 7.8.2024, ELI: http://data.europa.eu/eli/C/2024/4990/oj (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
Official Journal |
EN C series |
|
C/2024/4990 |
7.8.2024 |
Prior notification of a concentration
(Case M.11609 – KKR / IMPILO / IMMEDICA)
Candidate case for simplified procedure
(Text with EEA relevance)
(C/2024/4990)
1.
On 30 July 2024, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).This notification concerns the following undertakings:
|
— |
Poseidon Bidco AB (‘Bidco’, Sweden), controlled by KKR & Co. Inc. (‘KKR’, US), |
|
— |
Impilo AB (‘Impilo’, Sweden), |
|
— |
Immedica Pharma Holding AB (‘Immedica Pharma AB’, Sweden). |
KKR and Impilo will acquire within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation joint control of the whole of Immedica Pharma AB.
The concentration is accomplished by way of purchase of shares.
2.
The business activities of the undertakings concerned are the following:|
— |
KKR, headquartered in US, is a global investment firm that offers alternative asset management as well as capital markets and insurance solutions, |
|
— |
Impilo, headquartered in Sweden, is a Nordic investment company with a sole focus on investments in companies operating in the pharmaceutical, medtech, specialist pharma services or other healthcare and related services industries, |
|
— |
Immedica Pharma AB, headquartered in Sweden, is a pharmaceutical company focused on the commercialization of medicines for rare diseases and specialty care products. Immedica Pharma AB is currently solely controlled by Impilo. |
3.
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.Pursuant to the Commission Notice on a simplified treatment for certain concentrations under Council Regulation (EC) No 139/2004 on the control of concentrations between undertakings (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.
4.
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.11609 – KKR / IMPILO / IMMEDICA
Observations can be sent to the Commission by email or by post. Please use the contact details below:
Email: COMP-MERGER-REGISTRY@ec.europa.eu
Postal address:
|
European Commission |
|
Directorate-General for Competition |
|
Merger Registry |
|
1049 Bruxelles/Brussel |
|
BELGIQUE/BELGIË |
(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).
ELI: http://data.europa.eu/eli/C/2024/4990/oj
ISSN 1977-091X (electronic edition)